Scottsdale, AZ (PRWEB) May 10, 2012
QualityStocks would like to highlight ImmunoCellular Therapeutics, Ltd., a publicly traded clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The company recently commenced a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma.
In the company’s news yesterday,
ImmunoCellular Therapeutics issued an update on clinical trial site activity and patient enrollment for its phase II clinical trial of ICT-107, the company’s cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme (GBM), the most aggressive malignant primary brain tumor.
The company reports that it has initiated the trial in 25 sites, and that it expects to enroll approximately 200 or more patients to treat 102 patients with HLA-A1/A2 immunological subtypes. There currently are 189 patients enrolled in the study, with final enrollment expected to be completed by the second quarter of 2012.
“We are excited with the enrollment progress made in the phase II clinical trial of ICT-107,” Manish Singh, Ph.D., president and CEO of ImmunoCellular stated in the press release. “We appreciate the continued support from leading medical centers and oncologists as we move our focus from enrollment to obtaining patient data.”
The phase II trial is a double-blind, placebo-controlled, 2:1 randomized study designed to evaluate ICT-107’s safety and efficacy as treatment for patients with newly diagnosed GBM.
The company’s phase I clinical study of ICT-107 in GBM demonstrated that 16 newly diagnosed patients who received the vaccine combined with standard of care of surgery, radiation, and chemotherapy had a two-year overall survival of 80 percent and a three-year survival of 55 percent vs. the 26 percent two-year and 16 percent three-year survival based on the historical standard of care treatment alone.
ImmunoCellular reports that no serious adverse treatment related symptoms were observed in any of the patients.
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit http://www.QualityStocks.net
To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage
To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.